ENvue Medical, Inc. (FEED) is making a practical move into the consumer medical supplies market, launching a line of over-the-counter ENFit syringes designed for both feeding and medication delivery.

"With the launch of our over-the-counter ENFit Syringes, available in institutional and consumer-friendly packaging, we are expanding access to safe, affordable, and standardized enteral delivery tools...," said Doron Besser, CEO of ENvue Medical.

What's Being Launched

The syringes will be available through online retailers including Amazon and durable medical equipment suppliers in four sizes: 2.5 mL, 5 mL, 10 mL, and 60 mL. No prescription required, which is the whole point here—making these tools more accessible for people who need them.

These aren't single-use throwaways either. The ENFit syringes are engineered for reuse for up to seven days or 20 uses, designed to support consistent and safe enteral delivery whether you're in a hospital setting or managing care at home.

The Bigger Picture

This launch fits into a broader strategic pivot. Back in December 2025, NanoVibronix Inc. changed its corporate name to ENvue Medical, signaling a shift in focus toward its ENvue feeding-tube placement system.

"Our strategy is now focused on scaling hospital utilization, strengthening our commercial footprint, and building a comprehensive enteral-feeding ecosystem around ENvue through both internal development and external business development opportunities," Besser said in a December 2025 press release.

Just last week, ENvue Medical launched a development program leveraging vibration-based technology from its NanoVibronix division. The goal? Addressing pain and discomfort associated with indwelling nasogastric tubes.

Nasogastric tubes are ubiquitous in hospital care and often need to stay in place for extended periods. While medically essential, they're commonly associated with nasal and throat discomfort during the time they're in use—a real quality-of-life issue for patients.

FEED Price Action: ENvue Medical shares were down 2.16% at $2.27 during premarket trading on Wednesday.